Medication Management for Diabetes

Introduction to Medications

The American Diabetes Association recommends Empagliflozin (Jardiance), Dapagliflozin (Farxiga), or Canagliflozin (Invokana) for patients with established cardiovascular disease or chronic kidney disease 1, 2
Sitagliptin (Januvia) or Linagliptin (Tradjenta) may be better tolerated in some patients, although less potent than GLP-1 receptor agonists for glycemic control and weight loss 2, 3

If other options fail, progression to insulin therapy (basal insulin with or without bolus insulin) may be necessary, particularly for patients with significant hyperglycemia 1

Combination therapy, such as combining medications with complementary mechanisms (e.g., GLP-1 RA + SGLT2 inhibitor), may be more effective than switching completely 1
The American College of Cardiology recommends avoiding the use of GLP-1 receptor agonists, including tirzepatide and semaglutide, in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, as well as in pregnant or breastfeeding women, due to potential risks 4
Patients with a history of pancreatitis should use GLP-1 receptor agonists with caution, as they may be at increased risk of exacerbating the condition 4

The American Diabetes Association recommends considering dual GIP/GLP-1 receptor agonists like tirzepatide for patients with type 2 diabetes who require superior glycemic control and weight loss efficacy, as demonstrated by the superior HbA1c reduction and weight loss of Mounjaro compared to semaglutide in head-to-head clinical trials 5
The dual mechanism of tirzepatide provides enhanced metabolic effects, explaining the superior efficacy of Mounjaro over semaglutide, a single GLP-1 receptor agonist 6
When switching from Ozempic to Mounjaro, the recommended starting dose is tirzepatide 2.5 mg weekly for 4 weeks, with gradual titration by 2.5 mg increments every 4 weeks as tolerated, and a target dose of 10-15 mg weekly for maximum efficacy 4

Consideration should be given to the timing of Mounjaro administration before elective procedures, as it can delay gastric emptying and potentially increase aspiration risk during general anesthesia 7
The dual receptor mechanism of tirzepatide may provide a more balanced effect on gastric emptying, potentially leading to better tolerability in patients experiencing GI side effects with semaglutide, although both medications have similar gastrointestinal side effect profiles 4

Insurance coverage for Mounjaro is often restricted to FDA-approved indications, and prior authorization may be required to prove FDA-approved diagnosis of type 2 diabetes 8
The American Medical Association suggests documenting specific glycemic targets not achieved with current Ozempic therapy, as well as any persistent diabetes complications, to support insurance approval for switching to Mounjaro 8